Mosaic ImmunoEngineering Inc.
For the period ended Dec 31, 2024. Filed Apr 15, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Apr 15, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Power of Attorney
Know all persons by these presents, that each person whose signature appears below constitutes and appoints Steven King and Paul Lytle, and each of them, as his/her true and lawful attorneys-in-fact and agents, with full power of substitution and re-substitution, for him/her and in his/her name, place, and stead, in any and all capacities, to sign any and all amendments to this Annual Report, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he/she might or could do in person, hereby ratifying and confirming that all said attorneys-in-fact and agents, or any of them or their or his/her substitute or substituted, may lawfully do or cause to be done by virtue thereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ Steven King | President and Chief Executive Officer, Director | |
| Steven King | Principal Executive Officer | April 15, 2025 |
| /s/ Paul Lytle | EVP, Chief Financial Officer, Director | |
| Paul Lytle | (Principal Financial and Accounting Officer) | April 15, 2025 |
| /s/ Robert Baffi, Ph.D. | ||
| Robert Baffi, Ph.D. | Director | April 15, 2025 |
| /s/ Robert Garnick, Ph.D. | ||
| Robert Garnick, Ph.D. | Director | April 15, 2025 |
Index to Consolidated Financial Statements
For the Years Ended December 31, 2024 and 2023
| Page | |
| Report of Independent Registered Public Accounting Firm (Rose, Snyder & Jacobs LLP PCAOB ID#: 468) | F-2 |
|---|---|
| Report of Independent Registered Public Accounting Firm (PCAOB ID 170) | F-3 |
| Financial Statements: | |
| Consolidated Balance Sheets | F-4 |
| Consolidated Statements of Operations | F-5 |
| Consolidated Statements of Stockholders’ Deficit | F-6 |
| Consolidated Statements of Cash Flows | F-7 |
| Notes to Consolidated Financial Statements | F-8 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.